Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Gastrointestinal Tumors
Interventions: DRUG: Sorafenib|DRUG: Capecitabine
Sponsor: Yale University
Collaborators: Bayer